Key data
| Regulation | Royal Decree 1003/2026, of November 18, approving the Statute of the State Agency for Public Health (AESAP) |
|---|---|
| Publication | November 20, 2026 |
| Entry into force | November 20, 2026 |
| Affected parties | Health administrations, public health professionals and general public |
| Category | Regulatory Changes |
| Year | 2026 |
| Responsible body | Ministry of Health |
| Source | BOE-A-2026-24299 |
The management of the next health emergencies in Spain will have a new and influential actor: the State Agency for Public Health (AESAP). Its statute, approved by Royal Decree 1003/2026, of November 18, enters into force on the same day of its publication in the BOE and represents the formal separation between the technical-scientific function and the management function within the Spanish public health system.
For executives, health managers and advisors working with the Administration, this is not a cosmetic change: it implies a new node of technical authority with which to coordinate, new participation channels and a reordering of competencies that affects how decisions are made in public health crises.
What does this regulation establish?
Royal Decree 1003/2026 approves the Statute of AESAP, a state agency attached to the Ministry of Health. Its creation responds to three simultaneous drivers:
- The milestones of the Recovery Plan (Next Generation EU funds), which required the creation of this agency as a binding condition.
- The recommendations of the WHO and ECDC (European Centre for Disease Prevention and Control) following lessons learned from the COVID-19 pandemic.
- The need to separate the technical function from the political-management function within the Ministry of Health.
The core functions assumed by AESAP are:
| Function | Description |
|---|---|
| Health risk surveillance | Continuous monitoring of threats to public health in Spain |
| Health risk assessment | Independent technical-scientific analysis of identified risks |
| Health risk communication | Transfer of information to citizens, professionals and administrations |
| R&D&I | Research, development and innovation as a core function of the agency |
| Inter-institutional coordination | Reference technical node with autonomous communities, universities and international organizations |
| Citizen participation | Formal mechanisms for citizen participation in the agency's activities |
A differentiating element is the adoption of the "One Health" approach, which integrates biomedical, veterinary and environmental perspectives. This expands the agency's scope of action beyond strict human health, incorporating the interface between animal health, ecosystems and human health.
The management functions—political decision, resource allocation, executive direction of crises—remain in the Ministry of Health. AESAP acts as the technical-scientific arm, not as a governing body.
Economic and operational impact
The Royal Decree does not establish fees, direct costs or sanctions for private companies. The impact is structural and operational, especially for entities that interact with the health administration:
- Internal competency redistribution: Autonomous communities, universities and international organizations will now have a differentiated technical interlocutor (AESAP) from the political-management interlocutor (the Ministry). This can speed up the technical response but requires adapting existing communication and coordination channels.
- Impact on health emergency management: AESAP will be the reference node in future crises. Organizations participating in emergency response (hospitals, laboratories, health service providers, specialized consultants) must learn the new coordination protocols and structures.
- R&D&I as a core function: The agency incorporates research as a central activity, which opens potential public-private collaboration channels for companies in the health, biotechnology and health technology sectors.
- Citizen participation mechanisms: Third sector organizations, professional associations and patient associations will have formal channels to interact with AESAP.
Who does it affect?
- Regional health administrations: Must adapt their technical coordination protocols to the new interlocutor (AESAP) for risk surveillance and assessment.
- Public health professionals: Epidemiologists, preventive medicine doctors, public health veterinarians and environmental technicians working in network with central administration.
- Universities and research centers: AESAP will act as a coordination node in R&D&I in public health, affecting agreements, projects and funding.
- International organizations with presence in Spain: WHO, ECDC and other organizations that coordinate with the Spanish Administration on health surveillance.
- Companies in the health, biotechnology and health technology sectors: Potential collaborators in the agency's R&D&I projects.
- Consulting and advisory firms specialized in public health: Must update their knowledge of the new institutional map to correctly advise their clients.
- General public: As recipients of health risk communication and with access to new participation mechanisms.
Practical example
An autonomous community that detects an outbreak of zoonotic disease (transmitted from animals to people) activates its alert protocols. Before AESAP, the technical assessment of risk and coordination with the Ministry of Health fell to the same body that made management decisions.
With the new framework, the regional health counselor has two differentiated interlocutors: AESAP, which provides the technical-scientific assessment of risk under the "One Health" approach (integrating the veterinary and environmental vector), and the Ministry of Health, which coordinates the management response. This allows the technical assessment to be more agile, independent and aligned with ECDC standards, while political decision remains in the hands of the Ministry.
For a company providing laboratory or diagnostic services that works with the Administration, this means that contracts and technical protocols for collaboration in epidemiological surveillance must be negotiated or validated with AESAP, not directly with the Ministry.
What should organizations do now?
- Identify if your organization interacts with central health administration: If you coordinate with the Ministry of Health on epidemiological surveillance, risk assessment or R&D&I in public health, AESAP will be your new technical interlocutor.
- Update the internal institutional map: Review the contacts, protocols and current agreements with the Ministry of Health to determine which ones will be managed with AESAP.
- Explore R&D&I collaboration opportunities: If you are a company in the health, biotechnology or health technology sector, AESAP incorporates research as a core function. Monitor the calls and collaboration frameworks published by the agency.
- Review health emergency protocols: Organizations participating in the response to health crises must update their plans to reflect AESAP's new role as a reference technical node.
- Follow the agency's regulatory development: The statute is the starting point. AESAP will develop its own operating rules, calls and protocols. Stay informed through the BOE and the Ministry of Health itself.
Frequently asked questions
What is AESAP and what functions does it have?
AESAP (State Agency for Public Health) is a state agency attached to the Ministry of Health created by Royal Decree 1003/2026. Its core functions are surveillance, assessment and communication of health risk, R&D&I in public health and coordination with autonomous communities, universities and international organizations such as the WHO and ECDC. It adopts the "One Health" approach, integrating biomedical, veterinary and environmental perspectives.
When does the AESAP Statute come into force?
Royal Decree 1003/2026 was published on November 20, 2026 and entered into force that same day. There is no transition period: the agency is formally constituted from the date of publication in the BOE.
What is the difference between AESAP and the Ministry of Health?
AESAP assumes the technical-scientific functions (surveillance, assessment and communication of health risk, R&D&I). Management functions—political decision, resource allocation, executive direction of crises—remain in the Ministry of Health. It is a separation between the technical arm and the political-management arm of the state public health system.
Why is AESAP created now?
Its creation responds to three factors: the milestones of the Recovery Plan (Next Generation EU funds) that required it as a binding condition, the recommendations of the WHO and ECDC following the COVID-19 pandemic, and the need to separate the technical function from the management function within the Ministry of Health.
Does AESAP affect private companies in the health sector?
It does not impose direct costs or sanctions on private companies. However, companies in the health, biotechnology and health technology sectors that collaborate with the Administration on epidemiological surveillance or R&D&I must update their interlocutors: AESAP will be the reference technical node instead of the Ministry of Health for these matters. It also opens opportunities for collaboration in research projects.
Official source
Consult complete regulation in official source
Notice: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2026-24299